China Healthcare:What to expect for ASCO
ASCO abstract titles were released online earlier this morning
We summarize key data presentation in Figure 1on the next page for Chinesecompanies, while highlighting the following: 1) Anlotinib P3data in 3L NSCLC;2) Fruquintinib P3data in 3L CRC; 3) BGB-A317(PD-1) P1data; 4)DTRMWXHS-12(BTK inhibitor from Hisun Pharma) P1data. According to theASCO website, the abstracts will be released on May 17.